Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts

• DOI: 10.1073/pnas.0437788100
• Publication Date: 2003-02-18T20:04:50Z
• Authors: Meili Zhang; Zhuo Zhang; Kayhan Garmestani; Jody Schultz; Donald B. Axworthy; Carolyn K. Goldman; Martin W. Brechbiel; Jorge A. Carrasqu...; Thomas A. Waldmann
• Keywords: Leukemia; Lymphoma; Recombinant Fusion Proteins; Transplantation, Heterologous; Antibodies, Monoclonal; Receptors, Interleukin-2; Radioimmunotherapy; 3. Good health; Mice; 03 medical and health sciences; 0302 clinical medicine; Animals; Streptavidin

Although radioimmunotherapy with radiolabeled intact monoclonal antibodies has demonstrated efficacy in the treatment of lymphoma, it provides low tumor-to-normal-tissue radionuclide target ratios and unwanted prolonged radiation exposure to bone marrow. To overcome these obstacles, administration was separated from that antibody by using an anti-IL-2 receptor α single chain Fv-streptavidin fusion protein, followed biotin treat lymphoma or leukemia xenografted mice. This Pretarget approach provided extremely rapid effective tumor targeting, permitting use short-lived α-emitting radionuclides. With β-emitter 90 Y, all 10 lymphoma-xenografted mice were cured. α-emitter 213 Bi, significant obtained treating leukemic mice, and, furthermore, when combined immunotherapy, 7 Thus, is very promising could represent next generation leukemia.